Avricore Health Business Summary

Avricore Health Inc. (TSXV: AVCR, OTCQB: AVCRF) operates as a pharmacy service innovator, primarily generating revenue through its proprietary HealthTab™ platform, a turnkey point-of-care testing (POCT) solution. The company’s multi-stream revenue model includes equipment leasing, sales of consumables (test kits), direct access testing fees, and the monetization of real-world data (RWD) sets for clinical trials and health organizations. Business segments are geographically divided between its legacy Canadian operations and its rapidly expanding United Kingdom division, where it has secured strategic partnerships with NHS Integrated Care Boards in North East and North Central London. Avricore competes directly with point-of-care diagnostic providers such as QuidelOrtho Corporation, Diagnos Inc., and Cue Biopharma. Within this landscape, Avricore distinguishes itself by transforming community pharmacies into proactive diagnostic hubs, bridging the gap between traditional laboratory testing and accessible primary care. The leadership team is currently headed by CEO Rodger Seccombe, who was appointed in June 2025 and previously served as the company’s Chief Technology Officer and the Co-Founder of HealthTab™. Seccombe, a CPA with over 20 years of experience in software and health informatics, is supported by CFO Kiki Smith, a seasoned financial executive with a background in regulatory compliance and corporate transformations. The Board of Directors is led by Independent Chairman David Hall and includes notable members such as Christine Hrudka, a former Chair of the Canadian Pharmacy Association, and Thomas W. Teahen, former CEO of the Ontario Workplace Safety and Insurance Board. This executive core recently oversaw a strategic transition from former CEO Hector Bremner to focus on international scale-up, supported by investor relations advisory from Oak Hill Financial.